BERLIN, Dec. 1 /PRNewswire/ -- The "International Aspirin(R) Senior Award 2000" is being conferred today on the founders of the "Antiplatelet Trialists' Collaboration," Colin Baigent, Rory Collins, Sir Richard Peto and Peter Sleight. Scientists at Oxford University, they played a major role in the meta-analyses of clinical trials confirming the effect of acetylsalicylic acid (ASA) in the prevention of heart attacks and strokes. The foursome founded the "Antiplatelet Trialists' Collaboration," an international group of scientists involved in clinical studies with drugs that inhibit the clumping together of blood platelets. This aggregation is a vital part of the natural process for closing wounds. If it occurs inside blood vessels, however, it may cause a heart attack or stroke. The "Oxford Group" members are also closely associated with a number of scientific studies considered to be milestones in ASA research. The "International Aspirin(R) Awards are presented annually by Bayer AG to support research into the enormous medical opportunities offered by ASA, which was originally developed in a Bayer laboratory. Winners are selected by an International Advisory Board of 11 leading scientists from various fields of medicine. The Senior Award is worth a total of DM 50,000. In addition to the Senior Award, a "Young Researchers' Aspirin(R) Award" is also given. The "Young Researchers' Aspirin(R) Award" is worth a total of DM 20,000. This year, the "Young Researchers' Aspirin(R) Award 2000" is being awarded to the Brazilian biochemist Marcela F. Lopes and Anthony Rodgers, a doctor from New Zealand. In work submitted for the award, Dr. Lopes showed that acetylsalicylic acid has an inhibitory effect on the organism that causes Chagas' disease. This often fatal infectious disease is transmitted by parasites and is common in South America. Dr. Rodgers was selected for the award on the basis of his study, the largest of its kind, of the prophylaxis of venous thrombosis following joint surgery. The study followed more than 17,400 patients who took 160 milligrams of acetylsalicylic acid daily over a 35-day period. The result was a 29 percent reduction in the number of symptomatic deep vein thromboses and a reduction in the incidence of pulmonary embolism by as much as 43 percent. "The International Senior Aspirin(R) Award is an outstanding opportunity for Bayer to recognize and thank those scientists who have put so much of their scientific creativity and effort at the service of acetylsalicylic acid," said Gary S. Balkema, General Manager of the Consumer Care Business Group at Bayer AG. "In presenting the Young Researchers' Aspirin Award, we are able to encourage young scientists to continue writing new chapters of the Aspirin success story in the search for ever-new areas of application." Originally developed to relieve pain, the active ingredient in Aspirin(R) has gained prominence in many other medical indications, including the prevention of heart attacks and strokes, acute therapy of myocardial infarction, and the therapy of angina pectoris and migraine. Numerous international studies are currently investigating the action of ASA in the prevention of some types of cancer. Around 3,500 scientific papers on Aspirin(R) and the active ingredient acetylsalicylic acid are published every year.
SOURCE Bayer Corporation